跳至主要内容
临床试验/NCT01881282
NCT01881282已完成4 期

A Comparative Clinical Research on Therapeutic Effect and Safety of Compound Carraghenates Cream Versus Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids

Xian-Janssen Pharmaceutical Ltd.1 个研究点 分布在 1 个国家目标入组 123 人开始时间: 2006年12月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
123
试验地点
1
主要终点
Pain Intensity Score at Day 4

研究概览

简要总结

The purpose of this study is to compare the therapeutic effect and safety of compound carraghenates cream with Mayinglong musk hemorrhoid (swollen veins in the lower part of the rectum or anus) ointment in the treatment of hemorrhoids, especially regarding the relief of pain.

详细描述

This is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team work on a medical research study), controlled clinical trial and comparative study of safety and efficacy of compound carraghenates cream with Mayinglong musk hemorrhoid ointment in the treatment of hemorrhoids, especially regarding the relief of pain. Participants will be randomly assigned to either of the two treatment groups that are carraghenates cream (Titanoreine) group or Mayinglong musk hemorrhoid ointment group. The total duration of the study will be 1 Week (7 days). In carraghenates cream group, 3-4 gram (g) cream will be administered each time through anal canal, twice a day, once in the morning and once in the evening for consecutive 6 days and in the Mayinglong musk hemorrhoid ointment group, 2 g ointment will be administered each time through anal canal, twice a day, once in the morning and once in the evening for consecutive 6 days. Efficacy will be assessed by using Numeric Rating Scale (NRS) and participants' safety will be monitored throughout the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 75 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants who agree to participate in the current study
  • Participants having painful hemorrhoids (swollen veins in the lower part of the rectum or anus [external hemorrhoid, mixed hemorrhoid, etc.])
  • Participants who did not use other topical drugs to treat their hemorrhoids a day before the inclusion
  • Participants who do not use drugs other than the study drug and the control drug to treat their hemorrhoids during the study period

排除标准

  • Participants having other anorectal diseases , such as anal fistula , anal cleft , perianal abscess , and anorectal occupied lesions etc
  • Participants having hypersensitive predisposition or hypersensitive to any of components of the study drugs
  • Female participants under pregnancy or during breastfeeding period
  • Participants who fail to accept the scheduled visits or are lost to the visits
  • Participants complicated by serious cardio cerebro vascular diseases, hepatic and renal diseases, diseases of hemopoietic system or mental disorders

研究组 & 干预措施

Mayinglong Musk Hemorrhoid Ointment

Active Comparator

干预措施: Mayinglong Musk Hemorrhoid Ointment (Drug)

Carraghenates Cream

Experimental

干预措施: Carraghenates Cream (Drug)

结局指标

主要结局

Pain Intensity Score at Day 4

时间窗: Day 4

Pain intensity will be measured on an 11-point numeric rating scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates intense pain. Grade 1-4 represents mild pain, Grade 5-6 moderate pain, and Grade 7-10 serious pain. Higher score indicates worsening.

Participants' Satisfaction for the Treatment

时间窗: Day 7

Participants' will assess for the treatment satisfaction on numeric rating scale (NRS) ranging from 1 to 5, where 1= Very unsatisfactory; 2= Unsatisfactory; 3=General; 4= Satisfactory; 5= Very satisfactory.

Pain Acting Time

时间窗: Day 1 up to Day 7

The time from the first administration of the drugs to the time when the participant feels that his (her) pain has been remitted remarkably will be assessed.

Pain Intensity Score at Day 7

时间窗: Day 7

Pain intensity will be measured on an 11-point numeric rating scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates intense pain. Grade 1-4 represents mild pain, Grade 5-6 moderate pain, and Grade 7-10 serious pain. Higher score indicates worsening.

Daily Duration of Symptoms

时间窗: Day 1 up to Day 7

The accumulated time of the onset of all symptoms in the same day will be assessed. The baseline value before the administration of the drugs is the accumulated time of the occurrence of all symptoms in the day prior to the visit.

Frequency of Defecation

时间窗: Day 1 up to Day 7

The daily frequency of defecation for the day prior to the visit and each day during the trial period will be assessed.

Assessment of Other Symptoms and Signs Including Bleeding, Edema, Local Discomfort, and Prolapse

时间窗: Day 1 up to Day 7

Participants will assess these symptoms on a score range of 0 to 3 where 0=none for all symptoms and 3= "Blood jets while defecating, and the blood jetting stops after defecation" for bleeding, "serious edema" for edema, "severe" for local discomfort and "it is difficult or unable to return the prolapsed pile" for prolapse.

次要结局

未报告次要终点

研究者

发起方
Xian-Janssen Pharmaceutical Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Comparative Efficacy and Safety Study of Compound... | 临床试验